What place will tezepelumab hold in the treatment paradigm in chronic rhinosinusitis?

Expert Rev Clin Immunol. 2023 Jul-Dec;19(8):821-825. doi: 10.1080/1744666X.2023.2215986. Epub 2023 May 21.

Authors

Valentin Favier¹, Jérémy Charriot^{2

3}, Louis Crampette¹, Arnaud Bourdin^{2

3}, Engi Ahmed^{2

3

4}

Affiliations

¹ Department of ENT Surgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
² Department of Respiratory Diseases, Univ Montpellier, CHU Montpellier, Montpellier, France.
³ PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.
⁴ Laboratory of Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium.

PMID: 37194702
DOI: 10.1080/1744666X.2023.2215986

No abstract available

Keywords: Chronic Rhinosinusitis; T2 inflammation; Tezepelumab; asthma; biologics; eosinophils; nasal polyps.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Chronic Disease
Eosinophils
Humans
Nasal Polyps*
Rhinitis* / drug therapy
Sinusitis* / drug therapy

Substances

tezepelumab
Antibodies, Monoclonal, Humanized